Aadi bioscience reports interim results from precision1 trial of nab-sirolimus demonstrating anti-tumor activity in solid tumors with tsc1 or tsc2 inactivating alterations

Interim results from investigator-assessed responses in first 40 patients from tsc1 and tsc2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in precision1 supporting two-thirds interim analysis expected in 3q 2024 study on track for completion by end 2024; final data readout expected in early 2025 company to host conference call today at 5:00 pm est los angeles , dec. 14, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic precision1 trial evaluating nab-sirolimus in patients with tsc1 or tsc2 inactivating alterations.  "our tumor agnostic precision1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of tsc1 or tsc2, regardless of tumor type.
AADI Ratings Summary
AADI Quant Ranking